Clinical Trial Update: Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 trials are evaluating sintilimab as neoadjuvant and adjuvant therapy for resectable non-small cell lung cancer. The study status is active but not recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tyvyt (Sintilimab)

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING